Results 1 to 10 of about 7,390 (165)

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial. [PDF]

Ann Neurol
Objective To evaluate the effectiveness and safety of ocrelizumab in self‐identified black and Hispanic people with relapsing multiple sclerosis. Methods The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open‐label, single‐arm, phase 4 study, intentionally recruited underrepresented populations in ...
Amezcua L, Reder AT, Bernitsas E, Monson NL, Vartanian T, Wu GF, Saleh M, Okai A, Obeidat AZ, Sokhi D, Parekh R, Pei J, Harp C, Clayton D, Abioye I, Williams MJ, CHIMES Study Group.   +16 more
europepmc   +2 more sources

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. [PDF]

Ann Neurol
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Frisell T, Hedberg S, Piehl F.
europepmc   +2 more sources

Development and Validation of Cell-Based Bioassay for the Detection of Neutralizing Antibodies to Ocrelizumab in Human Serum Using Antibody-Dependent Cell-Mediated Cytotoxicity Test in a Reporter Cell Line Expressing FcγRIIIa [PDF]

Antibodies
Background/Objectives: Ocrelizumab is a humanized monoclonal antibody targeting CD20, approved for the treatment of adult patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Olga Strizhakova, Grigory Poroshin, Andrei Pershin, Yana Bakhareva, Ivan Shevchenko, Ivan Lyagoskin, Rakhim Shukurov, Ravil Khamitov   +7 more
doaj   +2 more sources

Effect of ocrelizumab on rates of retinal atrophy in relapsing multiple sclerosis [PDF]

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Background Ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis (MS). The effect of ocrelizumab, an anti-CD20 monoclonal antibody and highly-effective disease modifying therapy (DMT),
Brenna McCormack, Anna Bacchetti, Ting-Yi Lin, Giulia S. Moretti, Angeliki Filippatou, Georgios Gakis, Martin Maurice O’Donnell, Clare McGarvey Lambert, Nathanael J. Lee, Kaitlyn Ecoff, Simidele Davis, Gabriel Otero-Duran, Ananya Gulati, Adam Didouchevski, Ernest Lievers, Nicole Pellegrini, Omar Ezzedin, Jeffrey Lambe, Hussein Moussa, Kathryn Fitzgerald, Scott D. Newsome, Ellen M. Mowry, Elias S. Sotirchos, Peter A. Calabresi, Bardia Nourbakhsh, Shiv Saidha   +25 more
doaj   +2 more sources

Divergent Immunological and Neurotrophic Responses to CD20 Depletion in Relapsing and Progressive Multiple Sclerosis [PDF]

Neurology and Therapy
Introduction Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with distinct subtypes, relapsing MS (RMS) and primary progressive MS (PPMS), which differ in clinical course and underlying immunopathology.
Gudrun M. Körner, Thiemo M. Möllenkamp, Konstantin F. Jendretzky, Julian R. Kretschmer, Anna Christina Saparilla Pietschmann, Janna M. Siemer, Jarle von Hörsten, Franz F. Konen, Philipp Schwenkenbecher, Martin W. Hümmert, Franziska Bachhuber, Hayrettin Tumani, Roland Jacobs, Thomas Skripuletz, Stefan Gingele   +14 more
doaj   +2 more sources

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis [PDF]

Annals of Clinical and Translational Neurology
Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on ...
Kimberly H. Markowitz, Neha V. Safi, Iliana Pliska‐Bloch, Ulrike W. Kaunzner, Ha Luu, Mert Sisman, Yi Wang, Thanh D. Nguyen, Sandra Hurtado Rúa, Susan A. Gauthier   +9 more
doaj   +2 more sources

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022
Background Ocrelizumab and rituximab are frequently used treatments for multiple sclerosis (MS). Data on switching from rituximab to ocrelizumab is limited. Objectives To assess the frequency, severity, and factors of infusion related reactions (IRRs) in
Enrique Alvarez, Kavita V. Nair, Stefan Sillau, Ian Shelton, Rebecca Seale, Sean Selva, John Corboy, Timothy L Vollmer   +7 more
doaj   +1 more source

Confirmation of CD19+ B-Lymphocyte Depletion Prior to Intake of the Second Dose of Ocrelizumab in Multiple Sclerosis Patients

Biomedicines, 2023
The aim of the retrospective study was to compare the immunophenotyping of T-lymphocytes, B-lymphocytes, and natural killer cells before the administration of the first and the second dose of ocrelizumab in 22 patients with multiple sclerosis in a three ...
Marija Radmilo, Sanda Pavelin, Igor Vujović, Joško Šoda, Maja Rogić Vidaković   +4 more
doaj   +1 more source

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

Journal of Neuroinflammation, 2023
Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis (MS). However, it remains to be established whether certain B cell
Carla Rodriguez-Mogeda, Zoë Y. G. J. van Lierop, Susanne M. A. van der Pol, Loet Coenen, Laura Hogenboom, Alwin Kamermans, Ernesto Rodriguez, Jack van Horssen, Zoé L. E. van Kempen, Bernard M. J. Uitdehaag, Charlotte E. Teunissen, Maarten E. Witte, Joep Killestein, Helga E. de Vries   +13 more
doaj   +1 more source

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

Frontiers in Immunology, 2023
We aimed to assess the long-term safety and effectiveness of ocrelizumab in a cohort of patients with multiple sclerosis (MS) at high risk of progressive multifocal leukoencephalopathy (PML), previously treated with natalizumab in extending interval ...
Pilar Santiago-Setien, Cristina Barquín-Rego, Paula Hernández-Martínez, María Ezquerra-Marigomez, Marta Torres-Barquin, Cristina Menéndez-Garcia, Fernando Uriarte, Yésica Jiménez-López, Mercedes Misiego, Jose Ramón Sánchez de la Torre, Sonia Setien, Manuel Delgado-Alvarado, Manuel Delgado-Alvarado, Javier Riancho, Javier Riancho, Javier Riancho, Javier Riancho   +16 more
doaj   +1 more source